Minovia Therapeutics is pleased to announce that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Technology (MAT) platform.
Read the full press release here: https://t.co/BtZYwW4I3U
#Minovia #Mitochondria #MitochondrialMedicine #MitochondrialAugmentationTechnology
From bench to patient, Minovia Therapeutics is advancing Mitochondrial Augmentation Technology (MAT) as a potential new treatment for Myelodysplastic Syndrome (MDS).
At the Targeting Mitochondria conference, hosted by the World Mitochondria Society, Dr. Tina Napso, PhD, presented results showing that MAT-treated cells from low-risk MDS patients achieved higher erythroid differentiation and engraftment, restoring energy balance without new mutations.
MAT brings mitochondrial therapy one step closer to transforming care for bone marrow disorders.
#TargetingMitochondria2025 #Mitochondria #MDS #MitochondrialTherapy #Hematopoiesis #StemCells #RegenerativeMedicine
At Minovia Therapeutics, science is the cornerstone of our mission to advance transformative therapies. Our multidisciplinary team is committed to harnessing cutting-edge methodologies and the latest advancements in mitochondrial and stem cell biology to propel our proprietary Mitochondrial Augmentation Technology (MAT) platform forward.
The MAT platform exemplifies our dedication to combining robust scientific discovery with scalable manufacturing processes, with the overarching goal of delivering meaningful therapies to patients affected by mitochondrial dysfunction.
We invite fellow scientists, clinicians, and industry partners to join us in realizing the full potential of mitochondrial science and advancing the future of cellular therapeutics: https://t.co/KvHnDFmBaE
#MinoviaTherapeutics #MitochondrialMedicine #ScientificExcellence #Collaboration #Innovation #MATplatform
We are proud to highlight the leadership and scientific vision of Dr. Noa Sher, our Chief Scientific Officer.
Under Noa’s leadership, our team is pioneering Mitochondrial Augmentation Technology (MAT), a proprietary platform that addresses the root causes of mitochondrial diseases and is already demonstrating clinical promise. Her dedication to innovation, patient needs, and scientific excellence continues to inspire and guide Minovia’s mission to deliver transformative treatments.
Learn more about our executive team: https://t.co/wxZn8ZuQ9F
#Minovia #ChiefScientificOfficer #MinoviaLeadership #MAT #CellTherapy #MitochondrialMedicine
This week, we stand in solidarity with the global community in recognizing Mitochondrial Disease Awareness Week, a time dedicated to raising understanding of the challenges faced by individuals and families living with mitochondrial disorders.
At Minovia Therapeutics, mitochondria are at the heart of everything we do. Our mission is to transform the lives of patients through innovative cell and mitochondrial therapies that target mitochondrial dysfunction at its source. By advancing scientific discovery and collaboration across the rare disease community, we remain committed to driving hope, awareness, and progress for those impacted.
Together, we can shine a light on mitochondrial disease, accelerate the path toward better treatments, and honor the strength of patients and caregivers worldwide.
#Minovia #MitochondrialDiseaseAwareness #RareDisease #CellTherapy #InnovationInHealthcare
At Minovia, we are pioneering the next generation of therapies with our Mitochondrial Augmentation Technology (MAT) platform. Our mission is to address both rare genetic mitochondrial diseases and age-related mitochondrial dysfunction disorders.
MNV-201 is currently in clinical trials for Pearson Syndrome – a primary mitochondrial disease and for Low-Risk Myelodysplastic Syndrome (MDS). Stay tuned for more updates as we continue to expand the MAT platform’s reach.
Learn more about our pipeline: https://t.co/UwVZZzNQtn
#Minovia #MitochondrialMedicine #InnovationInHealthcare #ClinicalDevelopment #MATPlatform
Minovia Therapeutics is grateful and pleased to announce that it has been awarded a $350,000 grant from @Countdown4ACure to support its research proposal focused on the development of novel mitochondrial blood-based biomarkers.
Press Release: https://t.co/1z6MC6KIBK
#Minovia #MitochondrialMedicine #BiotechInnovation #Biomarkers #LifeSciences #CountdownForACure
We are honored that The Sunday Telegraph has highlighted Minovia Therapeutics and our work in the field of mitochondrial transplantation, a pioneering therapeutic approach with the potential to address ageing and age-related diseases.
Learn more: https://t.co/Msqh54hz2m
#MinoviaTherapeutics #CellTherapy #Mitochondria #Longevity #HealthyAgeing #MitochondrialDisease
Minovia Therapeutics announces positive interim results of the ongoing Phase 2 trial of the Company’s lead investigational compound MNV-201 in Pearson Syndrome, a fatal pediatric mitochondrial disease characterized by sideroblastic anemia (a disorder causing abnormal red blood cell development), failure to thrive and exocrine pancreas dysfunction.
Press Release: https://t.co/d0EK4AjIET
#MinoviaTherapeutics #MNV201 #PearsonSyndrome #MitochondrialDisease #RareDisease
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
https://t.co/gaYF1OVRZ0
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
https://t.co/KUk3ZVM6WT